7-Ketolithocholic acid (Synonyms: 7-KLCA, 7-keto LCA, 7-oxo LCA, 7-keto Lithocholate, 7-oxo Lithocholate, 7-oxo Lithocholic Acid, NSC 226118) |
| Catalog No.GC39474 |
7-Ketolithocholic acid (3 α-hydroxy-7-oxygen-5 β-cholic 산)은 일종의 담 즙 산, 7-Ketolithocholic acid 흡수 될 수 있고, 7-Ketolithocholic 산성의 생산을 억제 내생 담 즙 산, 그리고 담도 cholestero의 분비에 영향을 줄 수 있다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 4651-67-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
7-Ketolithocholic acid (3 α-hydroxy-7-oxygen-5 β-cholic 산)은 일종의 담 즙 산, 7-Ketolithocholic acid 흡수 될 수 있고, 7-Ketolithocholic 산성의 생산을 억제 내생 담 즙 산, 그리고 담도 cholestero의 분비에 영향을 줄 수 있다.
14일 후 7-ketolithocholic acid (400 mg/day)를 경구 투여하였을 때 담즙의 담즙산 성분은 변화하였다:담즙산의 비율은 감소 (45%에서 19%), deoxycholic acid는 감소 (15%에서 10%), chenodeoxycholic acid는 눈에 띄게 증가 (36%에서 59%), ursodeoxycholic acid는 증가 (36%~ 59%), ursodeoxycholic acid는 증가 (2%~ 7%), lithocholic acid는 증가 (2%~ 5%) 하였으며, 7-ketolithocholic acid는 미량만 검출되었다.이 치료를 받는 동안 담도 암석화지수는 2.6에서 0.9로 감소하였고 담도 콜레스테롤 농도도 현저히 감소하였다.
References:
[1]. Choucair I, Nemet I, et,al. Quantification of bile acids: a mass spectrometry platform for studying gut microbe connection to metabolic diseases. J Lipid Res. 2020 Feb;61(2):159-177. doi: 10.1194/jlr.RA119000311. Epub 2019 Dec 9. PMID: 31818878; PMCID: PMC6997600.
[2]. Salen G, Verga D, et,al. Effect of 7-ketolithocholic acid on bile acid metabolism in humans. Gastroenterology. 1982 Aug;83(2):341-7. PMID: 7084613.
| 임상 실험[1]: | |
동물 모형 | 담석을 가진 5명의 남성 피험자 (평균 연령, 55세) |
제조 방법 | 매일 각 환자에게 400mg의 일관된 표시 7-ketolithocholic acid (특이활동, 1000 * 100 dpm/mg)을 일일이 복용시키고 2주간 그리고 담즙에서 치노데옥시콜산과 우르소데옥시콜산의 특이활동을 짝수일마다 측정하였습니다. |
제형 | 2주 동안 매일 400mg (정맥 주사) |
응용 분야 | 7-ketolithocholic acid은 흡수되어 내원성 담즙산 생산과 담즙의 콜레스테롤 분비를 억제합니다. |
참고문헌： [1]. Salen G, Verga D, et,al. Effect of 7-ketolithocholic acid on bile acid metabolism in humans. Gastroenterology. 1982 Aug;83(2):341-7. PMID: 7084613. | |
| Cas No. | 4651-67-6 | SDF | |
| Synonyms | 7-KLCA, 7-keto LCA, 7-oxo LCA, 7-keto Lithocholate, 7-oxo Lithocholate, 7-oxo Lithocholic Acid, NSC 226118 | ||
| Canonical SMILES | C[C@H](CCC(O)=O)[C@H]1CC[C@@]2([H])[C@]3([H])C(C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)=O | ||
| Formula | C24H38O4 | M.Wt | 390.56 |
| Solubility | DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: 30 mg/ml,Ethanol:PBS (pH 7.2) (1:3): 0.25 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5604 mL | 12.8021 mL | 25.6043 mL |
| 5 mM | 512.1 μL | 2.5604 mL | 5.1209 mL |
| 10 mM | 256 μL | 1.2802 mL | 2.5604 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 39 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *